EGFR-TKIs联合化疗一线治疗晚期EGFR基因突变非小细胞肺癌患者的疗效观察  

Efficacy of EGFR-TKIs combined with chemotherapy in the first-line treatment of advanced non-small cell lung cancer with EGFR gene mutation

作　　者：文苗苗 夏靖华 孙盈 王雪娇 张晏宁 张娇 张志培 姜涛 WEN Miaomiao;XIA Jinghua;SUN Ying;WANG Xuejiao;ZHANG Yanning;ZHANG Jiao;ZHANG Zhipei;JIANG Tao(Department of Thoracic Surgery,the Second Affliated Hospital of Air Force Medical University,Shaanxi Xi'an 710038,China)

机构地区：[1]空军军医大学第二附属医院胸腔外科,陕西西安710038

出　　处：《现代肿瘤医学》2022年第21期3905-3910,共6页Journal of Modern Oncology

摘　　要：目的:分析比较表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKIs)联合化疗与EGFR-TKIs单药一线治疗晚期非小细胞肺癌(NSCLC)的疗效和安全性。方法:回顾性分析2010年09月至2015年12月晚期EGFR突变阳性NSCLC患者100例,根据治疗方案分为联合组(50例)和单药组(50例),联合组采用EGFR-TKIs联合化疗治疗,单药组采用EGFR-TKIs单药治疗。比较两组患者的治疗效果、预后情况以及毒副作用。结果:联合组总有效率为66%(33/50),单药组为48%(24/50),组间比较差异无统计学意义(P=0.106);联合组的疾病控制率为88%(44/50),单药组的疾病控制率为68%(34/50),组间比较差异有统计学意义(P=0.028)。联合组和单药组的中位PFS分别为18.5个月和13.5个月,差异有统计学意义(P=0.013),两组的OS分别为36个月和28.5个月,差异无统计学意义(P=0.071)。单药组和联合组的3-4级治疗相关不良反应发生率分别为6%和10%,差异无统计学意义(P=0.463)。结论:与EGFR-TKIs单药相比,EGFR-TKIs联合化疗一线治疗晚期EGFR基因突变NSCLC患者,可提高PFS,且不良反应可耐受。Objective:To compare efficacy and safety of epidermal growth factor receptor tyrosine kinase inhibitor(EGFR-TKIs)combined with chemotherapy versus single EGFR-TKIs for advanced non-small cell lung cancer(NSCLC).Methods:100 NSCLC patients with EGFR gene mutation were retrospective analyzed from September 2010 to December 2015,and divided into the combination group(n=50)and single group(n=50).The combination group was treated with EGFR-TKIs combined with chemotherapy,and the single group was treated with EGFR-TKIs.After treatment,clinical efficacy,survival and toxicity were compared in the 2 groups.Results:The total effective rate in the combination group was 66%(33/50)and the total effective rate in the signal group was 48%(24/50).There were no significant differences in the total effective rate between the 2 groups(P=0.106).The disease control rate in the combination group was 88%(44/50)and the disease control rate in the signal group was 68%(34/50).There were significant differences in the disease control rate between the 2 groups(P=0.028).The median progression-free survival(PFS)was significantly longer in combination group than in single group(18.5 months vs 13.5 months,P=0.013).Overall survival(OS)was no significant between the two groups(36 months vs 28.5 months,P=0.071).The incidence of sever adverse events(grade 3-4)were less common with single group(6%)than combination group(10%)(P=0.463).Conclusion:Compared with EGFR-TKIs single,the combination of EGFR-TKIs and chemotherapy can prolong the PFS compared with EGFR-TKIs alone for the first-line treatment of NSCLC with EGFR mutation-positive,and the adverse reactions were tolerable.

关 键 词：化疗 非小细胞肺癌 EGFR-TKIS PFS OS 

分 类 号：R734.2[医药卫生—肿瘤]